Literature DB >> 20085465

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.

Helen Kovari1, Bruno Ledergerber, Manuel Battegay, Andri Rauch, Bernard Hirschel, Alain Kenfak Foguena, Pietro Vernazza, Enos Bernasconi, Nicolas J Mueller, Rainer Weber.   

Abstract

BACKGROUND: Chronic liver disease in human immunodeficiency virus (HIV)-infected patients is mostly caused by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult to diagnose.
METHODS: We studied the incidence of and risk factors for chronic elevation of ALT levels (greater than the upper limit of normal at 2 consecutive semi-annual visits) in participants of the Swiss HIV Cohort Study without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who were seen during the period 2002-2008. Poisson regression analysis was used.
RESULTS: A total of 2365 participants were followed up for 9972 person-years (median age, 38 years; male sex, 66%; median CD4+ cell count, 426/microL; receipt of antiretroviral therapy [ART], 56%). A total of 385 participants (16%) developed chronic elevated ALT levels, with an incidence of 3.9 cases per 100 person-years (95% confidence interval [CI], 3.5-4.3 cases per 100 person-years). In multivariable analysis, chronic elevated ALT levels were associated with HIV RNA level >100,000 copies/mL (incidence rate ratio [IRR], 2.23; 95% CI, 1.45-3.43), increased body mass index (BMI, defined as weight in kilograms divided by the square of height in meters) (BMI of 25-29.9 was associated with an IRR of 1.56 [95% CI, 1.24-1.96]; a BMI 30 was associated with an IRR of 1.70 [95% CI, 1.16-2.51]), severe alcohol use (1.83 [1.19-2.80]), exposure to stavudine (IRR per year exposure, 1.12 [95% CI, 1.07-1.17]) and zidovudine (IRR per years of exposure, 1.04 [95% CI, 1.00-1.08]). Associations with cumulative exposure to combination ART, nucleoside reverse-transcriptase inhibitors, and unboosted protease inhibitors did not remain statistically significant after adjustment for exposure to stavudine. Black ethnicity was inversely correlated (IRR, 0.52 [95% CI, 0.33-0.82]). Treatment outcome and mortality did not differ between groups with and groups without elevated ALT levels.
CONCLUSIONS: Among patients without hepatitis virus co-infection, the incidence of chronic elevated ALT levels was 3.9 cases per 100 person-years, which was associated with high HIV RNA levels, increased BMI, severe alcohol use, and prolonged stavudine and zidovudine exposure. Long-term follow-up is needed to assess whether chronic elevation of ALT levels will result in increased morbidity or mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20085465     DOI: 10.1086/649922

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

Review 1.  Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients.

Authors:  Gyongyi Szabo; Samir Zakhari
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  The association of HIV viral load with indirect markers of liver injury.

Authors:  J E Forrester; M S Rhee; B H McGovern; R K Sterling; T A Knox; N Terrin
Journal:  J Viral Hepat       Date:  2011-12-02       Impact factor: 3.728

3.  Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors.

Authors:  T J Nagu; M Kanyangarara; C Hawkins; E Hertmark; G Chalamila; D Spiegelman; F Mugusi; W Fawzi
Journal:  HIV Med       Date:  2012-03-14       Impact factor: 3.180

4.  Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.

Authors:  Pankaj Puri; Navjyot Kaur; Sunny Pathania; Sandeep Kumar; P K Sharma; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2017-01-07

5.  Human immunodeficiency virus infection and the liver.

Authors:  Megan Crane; David Iser; Sharon R Lewin
Journal:  World J Hepatol       Date:  2012-03-27

6.  HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women.

Authors:  Jason T Blackard; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Denise J Jamieson; Lytt Gardner; Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2011-01-19       Impact factor: 9.079

7.  Response to 'Is AST-to-platelet ratio index a reliable tool in HIV patients in Africa?'.

Authors:  Michael J Vinikoor; Edford Sinkala; Gilles Wandeler; Benjamin H Chi
Journal:  Liver Int       Date:  2015-02-25       Impact factor: 5.828

8.  Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C.

Authors:  Judith I Tsui; Debbie M Cheng; Howard Libman; Carly Bridden; Richard Saitz; Jeffrey H Samet
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

9.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

10.  Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.

Authors:  H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.